



Universiteit
Leiden
The Netherlands

HNPCC, molecular and clinical dilemmas

Wagner, A.

Citation

Wagner, A. (2005, April 27). *HNPCC, molecular and clinical dilemmas*. Macula, Boskoop.
Retrieved from <https://hdl.handle.net/1887/2719>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/2719>

Note: To cite this publication please use the final published version (if applicable).

3.3.

**Genetic testing in hereditary non-polyposis colorectal cancer families
with a *MSH2*, *MLH1* or *MSH6* mutation**

J Med Genet 2002;39;833-837

LETTER TO JMG

Genetic testing in hereditary non-polyposis colorectal cancer families with a *MSH2*, *MLH1*, or *MSH6* mutation

A Wagner, C Tops, JTWijnen, KZwinderman, CvanderMeer, MKets, MFNiermeijer, JGM Klijn, ATibben, HFA Vasen, HMeijers-Heijboer

J Med Genet 2002;39:833-837

About 5% of colorectal cancers are associated with the autosomal dominantly inherited cancer susceptibility syndrome hereditary non-polyposis colorectal cancer (HNPCC).^{1,2} HNPCC is characterised by a high risk of developing colorectal cancer and endometrial cancer at a young age (cumulative lifetime risk 80-90% and 30-40%, respectively), and by an increased risk of developing various other tumour types, such as ovarian, uroepithelial, small intestine, biliary tract, stomach, brain, and skin cancers.²⁻⁵ Germline mutations in one of three mismatch repair genes (*MSH2*, *MLH1*, and *MSH6*) were found to be responsible for a majority of HNPCC families.⁶⁻⁹

Knowledge of the causative mutation in a particular HNPCC family enables the identification of at-risk family members by genetic testing. Clearly, the absence or presence of a mutation is of considerable medical and psychological significance. Subjects not carrying the mutation are relieved from continuous anxiety and can be dismissed from medical surveillance, saving them trouble and reducing healthcare costs.¹⁰ Importantly, subjects with the mutation can benefit from a medical surveillance programme. For HNPCC, colonoscopy has been shown to be a potent tool for the detection and treatment of premalignant adenomas or early colorectal carcinomas in at-risk subjects, reducing the risk of developing colorectal cancer and decreasing the overall mortality by about 65%.^{11,12} The possibility of early detection of colorectal cancer by stool analysis using the genetic markers TP53, BAT26, and K-RAS raises expectations for the development of less invasive surveillance procedures.¹³ Furthermore, intervention trials with non-steroidal anti-inflammatory drugs (NSAID) in subjects at risk for developing colorectal cancer are in progress.^{14,15}

Sofar, studies on the use of genetic testing in HNPCC families have used families or subjects who had been registered for research purposes.^{10,16,17} It is conceivable, however, that these research families represent a selected group of HNPCC families where decision making processes are different from those in families in a clinical setting. Here, we report the use of genetic testing in 18 clinically ascertained HNPCC families with a known mutation in *MSH2*, *MLH1*, or *MSH6*.

MATERIAL AND METHODS

Patients

Eligible HNPCC families have been referred to the Department of Clinical Genetics of the Erasmus University Medical Centre Rotterdam for oncogenetic counselling by general practitioners and medical specialists since 1992. DNA analysis of the *MSH2*, *MLH1*, and *MSH6* genes was performed at the Department of Human and Clinical Genetics, Leiden University Medical Centre, as described previously.¹⁸⁻²⁰ Families were included in the study when a mutation in either of the three mismatch repair genes was identified before 2000. Subject of

Keypoints

- In a clinical setting, considerable interest was observed for genetic testing in HNPCC families with a known germline mutation.
- Testing was used more frequently by subjects with a higher pre-test genetic risk for the mutation, by women, and by subjects with children.
- Genetic testing has earned a place in the standard medical care for subjects at risk for HNPCC.

Table 1 Mutations in the *MLH1*, *MSH2*, and *MSH6* genes in the HNPCC families studied

Gene	Nature of the mutation (nucleotide change)	Families (n = 18)
<i>MSH2</i>	Genomic deletion exon 3	1
	Splice acceptor site intron 9 (IVS9_2A>G) 1	
	Frameshift mutation exon 2 (229_230delAG) 1	
	Nonsense mutation exon 13 (2038C>T) 1	
	Genomic deletion exon 1	2
	Nonsense mutation exon 8 (1285C>T)	
<i>MLH1</i>	Frameshift mutation exon 2 (1705_1706delGA) 1	
	Frameshift mutation exon 14 (2347delC) 1	
	Spliced donor site intron 8 (IVS8+1delG) 1	1
	Inframe deletion exon 16 (1852_1854delAAG) 5	
<i>MSH6</i>	Spliced donor site exon 16 (1896G>A)	
	Splice acceptor site intron 9 (IVS9-1G>C) 1	

these families were included when they were aged 18 years and over at the time of molecular diagnosis in the family and when they had a pre-test genetic risk for carrying the mutation of 100%, 50%, or 25% (see results).

Procedure

In general, the initial search for the causative mutation had been performed on blood DNA of the youngest colorectal cancer patient in the family (the index subject). Identified mutations were confirmed in all relatives affected with an HNPCC-related tumour from which DNA samples were available. The initial counsellor and index subjects were asked to inform all the adult first and second degree relatives of patients with an HNPCC-related tumour about the genetic predisposition to cancer in their family. Written information to distribute among their family members was made available to them. This information included facts on the inheritance of the cancer susceptibility in their family, the

Table 2 Characteristics of the families studied

Gene	Families (n=18)	Mean number CRC/family	Mean age CRC (range)	Mean number EC/family	Mean age EC (range)
<i>MSH2</i>	9	4.8	43.8y(23–75)1		46.4y(30–54)
<i>MLH1</i>	8	5.4	43.7y(27–72)0.5		46.3y(41–82)
<i>MSH6</i>	1	7	60.4y(32–84)5		55y(50–60)

CRC, colorectal cancer. EC, endometrial cancer.

possibility of genetic testing, the risks of developing cancer, and the options for intervention. Relatives opting for genetic testing received one or more individual pre-test counselling sessions according to the recommendations of the American Society of Clinical Oncology,²¹ including the discussion of medical, genetic, and psychosocial aspects of genetic testing. Psychological support was offered to all subjects throughout the testing procedure. Disclosure of the test results followed within 6–12 weeks after blood sampling. Mutation carriers were referred to local specialists for follow up and surveillance. In The Netherlands, this surveillance comprises colonoscopy and gynaecological examination every one to two years. In this country, prophylactic colectomy is currently not offered to unaffected mutation carriers.

Data collection and statistical analysis

All data were collected from medical records. Descriptive statistics were used to establish test rates of genetic testing. The influence of pre-test genetic risk, gender, parenthood, and age on the use of genetic testing was first assessed by univariate analysis. Subjects were categorised into subjects younger than 50 years and subjects 50 years and older. The simultaneous influence of gender, parenthood, and age was also assessed by multivariate logistic regression analysis in the 50% risk subjects. Pre-test genetic risk had been excluded from the multivariate analysis, as about half of the data on parenthood and age were missing for the 25% risk subjects.

To assess the time dependent rate of genetic testing, Kaplan–Meier survival probabilities were calculated for 50% risk subjects with a first degree relative with an HNPCC related tumour. By doing so, we avoided including the time 25% risk subjects had to wait for the genetic test result of their parent.

RESULTS

A cohort of 18 consecutive HNPCC families was selected that had a known mutation in *MSH2* (n=9), *MLH1* (n=8), or *MSH6* (n=1) (table 1). All families were of European origin. Five apparently unrelated families had an identical *MLH1* mutation and two apparently unrelated families had an identical *MSH2* mutation (table 1). At the time of clinical ascertainment, 15 of the 18 families fulfilled the Amsterdam II criteria.²² Of the other three families, two families presented

with a single patient with colorectal cancer under the age of 40 years and one family had three patients with endometrial cancer and one patient with ovarian cancer, all diagnosed over the age of 50 years.²³ Specific details of the number of colorectal and endometrial cancers per family and ages of onset are listed in table 2.

The 18 selected families consisted of 523 living subjects with a 100% (n=60), 50% (n=308), or 25% (n=155) pre-test genetic risk of carrying the family specific mutation (table 3). For practical reasons, the subjects diagnosed with an HNPCC related tumour (n=56) and obligate carriers (n=4) were designated as having a 100% pre-test genetic risk. The subjects with a 50% risk had a first degree relative with an HNPCC related tumour (n=267) or a first degree relative who was a mutation carrier (n=41). The subjects with a 25% risk had a living unaffected parent with a 50% risk (n=64) or a parent with a 50% risk who had died without evidence of an HNPCC related tumour (n=91).

Genetic testing was used by 260 of 523 (50%) eligible subjects (table 3). A mutation was detected in 133 (51%) subjects, of whom 83 were unaffected. Of the subjects with a pre-test genetic risk of 100%, 50%, and 25% for carrying the mutation, 87%, 57%, and 21% respectively used genetic testing ($p<0.0001$ for 100% v 50%; $p<0.0001$ for 50% v 25%) (tables 3 and 4). Of the 25% risk subjects who had an unaffected 50% risk parent who did not opt for testing, only three of 64 (5%) subjects used genetic testing. In contrast, of the 25% risk subjects with a dead unaffected 50% risk parent, 30 of 91 (33%) subjects used genetic testing (table 4). The test rate among the 308 50% risk subjects was 62% in women versus 51% in men, suggesting a small but significant preference for women to use genetic testing ($p=0.041$, table 4). The test rate in 50% risk subjects with children was 70% versus 45% for those without children, indicating parenthood as a stronger positive predictor towards testing ($p<0.001$, table 4). The age of the subjects did not influence test rates (table 4). Multivariate analysis of the data was consistent with the univariate analysis, again indicating gender and parenthood as significant parameters for genetic test usage (table 4). The mean time of follow up after identification of the mutation in the family was 42 months (range 12–74 months). Forty-one percent of 50% risk subjects decided for genetic testing within one year. At a


Table 3 Genetic testing and outcome in 100%, 50%, and 25% risk carriers in the 18 HNPCC families

Pre-test risk 100% 50%	25%			Total
	Parent alive	Parent dead	Total	
Number 60	308	64	91	155
Tested	52 (87%)	175 (57%)	33 (33%)	260 (50%)
Mutation carrier	50 (96%)	80 (46%)	0	133 (51%)

Table 4 Genetic test use in relation to gender, parenthood, age, and pre-test genetic risk

	Total Tested (%)	Univariate	Multivariate
Gender*			
Females	15697(62)	p=0.041	p=0.045
Males	15278(51)		
Children*			
Yes	182127(70)	p<0.001	p=0.013
No	10748(45)		
Age*			
<50y	191104(55)	p=0.24	p=0.39
>50y	11772(62)		
Pre-test risk			
50%	308175(57)	p<0.0001	
25%	15533(21)		
25% risk carriers			
Parental	643(5)	p<0.0001	
Parental	9130(33)		

*In subjects with a pre-test genetic risk of 50%.

**Figure 1** Time dependent rate of genetic testing in subjects with a 50% pre-test genetic risk. The proportion of 50% risk carriers not having the genetic test is shown at 0, 6, 12, 24, and 36 months after the identification of the familial mutation. Only 50% risk carriers with a first degree relative with an HNPCC related tumour are included.

follow up at two years and three years after molecular diagnosis, 58% and 65% respectively of the 50% risk subjects were tested (fig 1).

DISCUSSION

To our knowledge, the present study is the first to evaluate the use of genetic testing for HNPCC in a clinical setting. Importantly, we determined the use of genetic testing in complete pedigrees, including all affected family members and their unaffected first and second degree relatives. This was done in 18 HNPCC families with an identified pathogenic mutation in *MSH2*, *MLH1*, or *MSH6*. These families were quite extensive, with an average of 29 study subjects per family. The use of genetic testing by 50% risk carriers in our families was 57%. This test rate was lower than the 75% test rate in a Finnish cohort of 446 subjects at similar risk for an HNPCC germline mutation.¹⁶ The Finnish subjects, however, had consented to registration and participation in research, which is likely to be positively correlated with interesting genetic testing. Also, the Finnish population is known for its positive attitude towards genetic testing.²⁴ In a Northern American study only 90 out of 208 subjects (43%) from four extended HNPCC

research families were tested.¹⁷ As the pre-test genetic risks of the study subjects were not specified, we cannot compare their data with ours.

We found that the magnitude of pre-test genetic risk for carrying the mutation was strongly correlated with test rates (87%, 57%, and 21% for 100%, 50%, and 25% risk subjects, table 3). This phenomenon has also been observed in other inherited diseases.²⁵⁻²⁷ Interestingly, 25% risk subjects with an unaffected 50% risk parent who was a liver arely opted for genetic testing (5%), whereas subjects with the same pre-test genetic risk but with a dead unaffected 50% risk parent used genetic testing in one-third of the cases (tables 3 and 4). This may be because the identification of the mutation in a child designates the parent as an obligate carrier and children from a living unaffected 50% risk subject may therefore be more likely to refrain from genetic testing in order not to overrule their parents' preference for "not knowing". Also, children may share strategies to cope with genetic risks with their parents. The slightly higher genetic test rates in women than men (62% v 51%) was also seen in another late onset inherited disease.²⁸ In HNPCC, however, the additional risk for endometrial cancer in female mutation carriers probably also influences the use of genetic testing. This significantly higher test rates among subjects with children compared to subjects without children (70% v 45%) has also been observed in families with inherited breast and ovarian cancer (HBOC).²⁵ These findings emphasize that knowledge of the cancer risks for offspring is a major reason for subjects to opt for genetic testing. The high test rate in the affected 100% risk subjects also seems to reflect this phenomenon, since their participation is pivotal especially for the identification and confirmation of the pathogenic mutation in the family, but generally has few medical implications for themselves.

A significant proportion of subjects was tested more than one year after the identification of the family specific mutation (65% of the 50% risk carriers at a follow up of three years) (fig 1). Interestingly, at our institute, the time period for deciding for genetic testing was strikingly longer for subjects at risk for HNPCC than for subjects at risk for HBOC (50% at 18 months versus 9 months).²⁵ The differences in time needed for decision making may perhaps be related to the one to two years interval for colonoscopy in HNPCC families versus the six months interval for breast surveillance in HBOC families.

Genetic testing rates depend on the natural history of the disease concerned, the success of treatment, the efficacy and acceptability of surveillance and prevention, and the costs involved.²⁸ The use of genetic testing in 50% risk subjects varies from about 20% in Huntington's disease (no interventions available, but relief of uncertainty and relevance for, for example, reproductive choices)^{26,29} to ~55% in hereditary breast and ovarian cancer (*BRCA1* and *BRCA2* genes, surveillance and prophylactic mastectomy, prophylactic oophorectomy, and chemoprevention available for female carriers), to ~90% in familial hypercholesterolaemia (lipid lowering treatment available).³¹ The 57% HNPCC genetic testing rate in 50% risk carriers reported here is similar to that of women with the same genetic risk for carrying a *BRCA1* or *BRCA2* mutation. This suggests that the total load of factors that influence the choice to opt for genetic testing in HNPCC equals that in HBOC. The efficacy of regular colonoscopy in HNPCC mutation carriers is more favourable compared to regular mammography in young women with a *BRCA1* or *BRCA2* mutation.^{11,32} This limited efficacy of mammography causes some women with a *BRCA1* or *BRCA2* mutation to opt for prophylactic mastectomy.^{25,30} Though colonoscopy is not as invasive as the prophylactic mastectomy in HBOC, the burden and violation of physical integrity of this surveillance may be an underestimated factor. Also, the additional risks for other HNPCC related cancers, like brain tumours, for which no

options for surveillance and prevention are available, can cause subjects to refrain from testing. Other reasons not to opt for testing might be fear of financial and social discrimination and inability to cope with a positive test result. Notably, in The Netherlands, cancer predisposition is no reason for exclusion by the health insurance companies, nor for denial of access to employment. It was shown that most tested subjects are able to cope with genetic testing for cancer predisposition in the short term, particularly also for HNPCC. More data on the long-term psychosocial impact of genetic testing for HNPCC as well as data on the reasons and psychosocial impact of refraining from genetic testing are needed.

From the data reported here, however, it can be concluded that there is considerable interesting genetic testing in subjects from HNPCC families with a known mutation. Also, in view of the reduction in morbidity and mortality upon surveillance of identified mutation carriers, genetic testing has earned a place in the standard medical care for people at risk for HNPCC.

ACKNOWLEDGEMENTS

We thank R. Sijmons, A. Bröcker-Vriends, M. Breuning, F. Menko, I. Kluit, M. Aussems, D. Lindhout, R. Oldenburg, M. Vliet, U. Moog, and I. v. d. Burg for their contribution to oncogenetic counselling.

Authors' affiliations

A. Wagner, C. van der Meer, M. Kets, M. F. Niermeijer, A. Tibben, H. Meijers-Heijboer, Department of Clinical Genetics, Erasmus Medical Centre, Rotterdam, The Netherlands

A. Wagner, C. Tops, J. T. Wijnen, Department of Human and Clinical Genetics, Leiden University Medical Centre, Leiden, The Netherlands

K. Zwinderman, Department of Medical Statistics, Leiden University Medical Centre, Leiden, The Netherlands

J. G. M. Klijn, Department of Medical Oncology, Erasmus University Medical Centre, Rotterdam, The Netherlands

H. F. A. Vasen, Foundation for the Detection of Hereditary Tumours, Leiden University Medical Centre, Leiden, The Netherlands

Correspondence to: Dr H. Meijers-Heijboer, Department of Clinical Genetics, University Hospital Rotterdam, Westzeedijk 114, 3016 AH Rotterdam, The Netherlands; meijers@kgen.fgg.eur.nl

REFERENCES

- Peel DJ, Ziogas A, Fox EA, Gildea M, Laham B, Clements E, Kolodner RD, Anton-Culver H. Characterization of hereditary non-polyposis colorectal cancer families from a population-based series of cases. *Cancer Inst* 2000;**92**:1517-22.
- Lynch HT, de la Chapelle A. Genetics susceptibility to non-polyposis colorectal cancer. *J Med Genet* 1999;**36**:801-18.
- Hampel H, Peltomäki P. Hereditary colorectal cancer: risk assessment and management. *Clin Genet* 2000;**58**:89-97.
- Vasen HF, Wijnen JT, Menko FH, Kleibouker JH, Taal BG, Griffioen G, Nagengast F, Meijers-Heijboer H, Bertariol, Varescol, Bisgaard M, Mohr J, Fodde R, Khan M. Cancer risk in families with hereditary non-polyposis colorectal cancer diagnosed by mutation analysis. *Gastroenterology* 1996;**110**:1020-7.
- Watson P, Vasen HF, Mecklin JP, Jarvinen H, Lynch HT. The risk of endometrial cancer in hereditary non-polyposis colorectal cancer. *Am J Med* 1994;**96**:516-20.
- Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary non-polyposis colon cancer. *Cell* 1993;**75**:1027-38.
- Bronner CE, Baker SM, Morrison PT, Warren G, Smith LG, Lescoe MK, Kane M, Earabino C, Lipford R, Lindblom A, Tannergård P, Bollag R, Godwin A, Ward D, Nordenskjöld M, Fishel R, Kolodner R, Liskay M. Mutation in the DNA mismatch repair gene homolog MSH1 is associated with hereditary non-polyposis colon cancer. *Nature* 1994;**368**:258-61.
- Akiyama Y, Sato H, Yamada T, Nagasaki H, Tsuchiya A, Abe R, Yuasa Y. Germ-line mutation of the hMSH6/GTBP gene in an atypical hereditary non-polyposis colorectal cancer kindred. *Cancer Res* 1997;**57**:3920-3.
- Miyaki M, Konishi M, Tanaka K, Kikuchi Y, Yanoshita R, Muraoka M, Yasuno M, Igarai T, Koike M, Chiba M, Mori T. Germ-line mutation of MSH6 as the cause of hereditary non-polyposis colorectal cancer. *Nat Genet* 1997;**17**:271-2.
- Stanley AJ, Gaff CL, Aittomäki AK, Fabre LC, Macrae FA, John D. Value of predictive genetic testing in management of hereditary non-polyposis colorectal cancer [HNPCC]. *Med Aust* 2000;**172**:313-16.
- Jarvinen H, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen L, Peltomäki P, de la Chapelle A, Mecklin JP. Controlled 15-year trial on screening for colorectal cancer in families with hereditary non-polyposis colorectal cancer. *Gastroenterology* 2000;**118**:829-34.
- Renkonen-Sinisalo L, Aarnio M, Mecklin JP, Jarvinen HJ. Surveillance improves survival of colorectal cancer in patients with hereditary non-polyposis colorectal cancer. *Cancer Detect Prev* 2000;**24**:137-42.
- Dong SM, Traverso G, Johnson C, Geng L, Favis R, Boynton K, Hibi K, Goodman S, D'Allesio M, Paty P, Hamilton SR, Sidransky D, Barany F, Levin B, Shuber A, Kinzler KW, Vogelstein B, Jen J. Detecting colorectal cancer in stool with the use of multiple genetic targets. *J Natl Cancer Inst* 2001;**93**:858-65.
- Burn JCP, Bishop DT, Mathers J. Diet and cancer prevention: the Concerted Action Polyp Prevention. *Proc Nutr Soc* 1998;**57**:183-6.
- Hawke E, Lubet R, Limburg P. Chemoprevention in hereditary colorectal cancer syndromes. *Cancer* 1999;**86**:2551-63.
- Aktan-Collan K, Mecklin JP, Jarvinen H, Nystrom-Lahti M, Peltomäki P, Soderling I, Uetla A, de la Chapelle A, Kääriäinen H. Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. *Int J Cancer* 2000;**89**:44-50.
- Lerman C, Hughes C, Trock BJ, Myers RE, Main D, Bonney A, Abbaszadeh MR, Hartly AE, Franklin B, Lynch JF, Lynch HT. Genetic testing in families with hereditary non-polyposis colon cancer. *JAMA* 1999;**281**:1618-22.
- Wijnen J, Vasen H, Khan PM, Menko FH, van der Klift H, van Leeuwen C, vanden Broek M, van Leeuwen-Cornelissen I, Nagengast F, Meijers-Heijboer H, Lindhout D, Griffioen G, Cats A, Kleibouker J, Varescol, Bertariol, Bisgaard M, Mohr J, Fodde R. Seven new mutations in hMSH2, an HNPCC gene, identified by denaturing gradient electrophoresis. *Am J Hum Genet* 1995;**56**:1060-6.
- Wijnen J, van der Klift H, Vasen H, Khan PM, Menko F, Tops C, Meijers-Heijboer H, Lindhout D, Møller P, Fodde R. MSH2 genomic deletions are a frequent cause of HNPCC. *Nat Genet* 1998;**20**:326-8.
- Wijnen J, Khan PM, Vasen H, Menko F, van der Klift H, vanden Broek M, van Leeuwen-Cornelissen I, Nagengast F, Meijers-Heijboer H, Lindhout D, Griffioen G, Cats A, Kleibouker J, Varescol, Bertariol, Bisgaard M, Mohr J, Fodde R. Majority of MLH1 mutations responsible for hereditary non-polyposis colorectal cancer cluster at the hexon region 15-16. *Am J Hum Genet* 1996;**58**:300-7.
- Statement of the American Society of Clinical Oncology. Genetic testing for cancer susceptibility, adopted on 20 February 1996. *J Clin Oncol* 1996;**14**:1730-6.
- Vasen HF, Watson P, Mecklin JP, Lynch HT. New clinical criteria for hereditary non-polyposis colorectal cancer [HNPCC, Lynch syndrome] proposed by the International Collaborative Group on HNPCC. *Gastroenterology* 1999;**116**:1453-6.
- Wagner A, Hendriks Y, Meijers-Heijboer EJ, de Leeuw WJ, Morreau H, Hofstra R, Tops C, Birk E, Bröcker-Vriends A, van der Meer C, Lindhout D, Vasen H, Breuning M, Cornelisse CJ, van Krimpen C, Niermeijer M, Zwinderman AH, Wijnen J, Fodde R. Atypical HNPCC owing to MSH6 germline mutations: analysis of a large Dutch pedigree. *J Med Genet* 2001;**38**:18-22.
- Hietala M, Hakonen A, Aro AR, Niemela P, Peltonen L, Aula P. Attitudes toward genetic testing among the general population and relatives of patients with severe genetic disease: a survey from Finland. *Am J Hum Genet* 1995;**56**:1493-500.
- Meijers-Heijboer EJ, Verhoog LC, Brekelmans CT, Seynaeve C, Tilanus-Linthorst MM, Wagner A, Dukell, Devilee P, vanden Ouweland A, van Geel AN, Klijn GM. Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation. *Lancet* 2000;**355**:2015-20.
- Maat-Kievit A, Vegter-vander Vlis M, Zoetewij M, Losekoot M, van Haeringen A, Roos R. Paradox of a better test for Huntington's disease. *J Neurol Neurosurg Psychiatry* 2000;**69**:579-83.
- van Rijn MA, de Vries BB, Tibben A, vanden Ouweland AM, Halley DJ, Niermeijer MF. DNA testing for fragile X syndrome: implications for parents and family. *J Med Genet* 1997;**34**:907-11.
- Evans JP, Skrzynia C, Burke W. The complexities of predictive genetic testing. *BMJ* 2001;**322**:1052-6.
- Craufurd D, Dodge A, Kerzin-Storarl, Harris R. Uptake of presymptomatic predictive testing for Huntington's disease. *Lancet* 1989;**ii**:603-5.
- Meijers-Heijboer H, van Geel B, van Putten WL, Henzen-Logmans SC, Seynaeve C, Menke-Pluymers MB, Bartels C, Verhoog L, vanden Ouweland A, Niermeijer M, Brekelmans C, Klijn GM. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. *N Engl J Med* 2001;**345**:159-64.
- Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, Scheerder RL, Kastelein JJ. Review of first 5 years of screening for familial hypercholesterolemia in the Netherlands. *Lancet* 2001;**357**:165-8.

- 32 **Breklemans CT**, Seynaeve C, Bartels CC, Tilanus-Linthorst MM, Meijers-Heijboer EJ, Crepin CM, van Geel AA, Menke M, Verhoog LC, vanden Ouweland A, Obdeijn IM, Klijn JGM. Effectiveness of breast cancer surveillance in BRCA1/2 gene mutation carriers and women with high familial risk. *J Clin Oncol* 2001;**19**:924-30.
- 33 **Dudok-de Wit AC**, Tibben A, Duivenvoorden HJ, Niermeijer MF, Passchier J, Trijsburg RW. Distress in individuals facing predictive DNA testing for autosomal dominant late-onset disorders: comparing questionnaire results with in-depth interviews. Rotterdam/Leiden Genetics Workgroup. *Am J Med Genet* 1998;**75**:62-74.
- 34 **Lodder L**, Frets PG, Trijsburg RW, Meijers-Heijboer EJ, Klijn JG, Duivenvoorden HJ, Tibben A, Wagner A, vander Meer C, vanden Ouweland A, Niermeijer M. Psychological impact of receiving a BRCA1/BRCA2 test result. *Am J Med Genet* 2001;**98**:15-24.
- 35 **Aktan-Collan K**, Mecklin JP, de la Chapelle A, Peltomäki P, Uutela A, Kääriäinen H. Evaluation of a counselling protocol for predictive testing for hereditary non-polyposis colorectal cancer. *J Med Genet* 2000;**37**:108-13.
- 36 **Aktan-Collan K**, Haukka A, Mecklin JP, Uutela A, Kääriäinen H. Psychological consequences of predictive testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. *Int J Cancer* 2001;**93**:608-11.



Want to know more?

Data supplements

Limited space in printed journals means that interesting data and other material are often edited out of articles; however, limitless cyberspace means that we can include this information online.
Look out for additional tables, references, illustrations.

www.jmedgenet.com

